Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses.

Headache · 2020 · PMC7496732 · PMID 32445498

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

A clear trend toward more responders is evident with all fremanezumab dose regimens compared to placebo by the 1st month, and continues throughout the 3‐month period.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.